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Abstract
Objective. To assess nurses’ knowledge, attitudes and practices (KAP) towards sponta-
neous adverse drug reactions (ADRs) reporting.
Methods. The mixed-method study was conducted following a quanti-qualitative se-
quential approach: a survey (using a KAP questionnaire) followed by a focus group was 
performed. 
Results. In the quantitative findings, responders (570 hospital nurses) declared that they 
were unaware of the pharmacovigilance system (58.1%, n = 331); where to find the re-
porting form (63.5%, n = 362); how fill it in (71.6%, n = 408); to whom and how to send 
it (65.8%, n = 375). Only 11.1% (n = 63) reported ADRs. The qualitative phase sup-
ported the quantitative findings and provided new information about other factors that 
condition ADR reporting: misinterpretation of the meaning of “reporting”, unawareness 
of nurses’ autonomy in ADR reporting and fear of consequences after ADR reporting.
Conclusion. Nurses are not fully aware of their role in ADR reporting. We recommend 
educational interventions and management changes. 
INTRODUCTION
Subsequent to the disaster that occurred in the nine-
teen-sixties with thalidomide, drug regulation systems 
were developed in many countries to monitor adverse 
drug reactions (ADR) [1]. Improving a good system for 
drug safety is an important indicator of social progress 
and a duty of every government [2]. 
In this contest, pharmacovigilance was founded as 
“the science and activity relating to the detection, as-
sessment, understanding and prevention of adverse ef-
fects or any other possible drug-related problem” [1]. 
After the medication has been approved, during the 
post-marketing phase, spontaneous ADR reporting is 
a cornerstone for evaluating and monitoring the drugs 
benefit-risk profile [3]. Following the analysis of the re-
ports and the causality assessment, the regulatory au-
thorities of pharmacovigilance may decide to change 
the labelling or remove the drug from the market [4]. 
ADR is defined by the World Health Organization 
(WHO) as “a response to a drug which is noxious and 
unintended, and which occurs at doses normally used 
in man for the prophylaxis, diagnosis, or therapy of dis-
ease, or for the modification of physiological function” 
[1]. 
Since July 2012 the new European Union pharmaco-
vigilance legislation [5, 6] introduced important chang-
es aimed to a better prevention, detection and assess-
ment of ADRs. Also the definition of ADR has been 
updated, including that any reaction should be reported 
also in cases of medication errors, overdose, off-label 
use [5]. In the European Union, these changes were 
due to new available data regarding the impact of ADRs 
on public health, as they are the fifth leading cause of 
death in hospitals. Specifically, ADRs are 5% of all hos-
pital admittances, are responsible for about 197 000 
deaths per year, with a social cost assessed at 79 billion 
euro [7]. Also, ADRs have a cost in the United States of 
some 30 billion dollar each year [8] and are the cause of 
10% (68/678) of hospitalisations in US Veterans’ Affairs 
Medical Centres [9].
A major issue to detect new and potential ADRs is 
under-reporting among healthcare providers. A system-
atic review has shown that only 6% of all ADRs are re-
ported [10]. Under-reporting among physicians could 
be explained by some attitudes, defined as “compla-
cency”, “fear”, “indifference”, “ambition”, “ignorance”, 
“diffidence”, and “lethargy” [11]. Partially in agreement, 
a recent systematic review has identified other attitude 
among healthcare providers such as “insecurity”, de-
scribed as the opinion that it is nearly impossible to 
determine causality of ADRs [12]. A qualitative study 
has evaluated four potential barriers to the spontaneous 
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reporting among hospital physicians: obstacles related 
to diagnosis and suspicion of ADRs, to clinical activi-
ties (i.e. lack of time, difficulties in filling out records), 
to organizing a hospital pharmacovigilance system and 
to potential conflicts (i.e. confidentiality with patients’ 
data, legal liability) [13]. However, the available scien-
tific literature on the under-reporting phenomena main-
ly derives from investigations on physicians [11-13]. 
The contribution of all healthcare providers is a key 
to good post market surveillance [5]. In particular, 
nurses are in a unique position to monitor the patient’s 
responses to drugs and, consequently, if necessary, re-
port potential ADRs [14-16]. For the development of 
clinical nursing expertise, more on the job experience 
could be required [17]. In particular, a recently study 
has shown that newly graduated nurses had a lack of 
pharmacological knowledge and skills to detect adverse 
drug effects [18]. Improving one’s own competence 
in ADRs reporting is a nurse’s duty. The Nursing and 
Midwifery Council includes adverse drug monitoring 
and reporting among the safety standards in the nurs-
ing management of medications [19]. Two studies [20, 
21] showed that nurses can contribute quantitatively 
and qualitatively in ADRs reporting and consequently, 
increase the safety related to the use of drugs. In fact, 
no difference in quality and quantity emerges when 
comparing nurses’ and physicians’ ADR reports [22]. 
However the nurse’s contribution on ADR reporting is 
still marginal in some Countries. Among spontaneous 
reports of suspected ADRs received by the Central Por-
tugal Regional Pharmacovigilance Unit from January 
2001 to October 2011, it is estimated that only 0.55% 
of nurses employed reported [23]. In Sweden, where 
some nurses have a specialized education on prescrib-
ing a limited selection of drugs, the number of ADR 
reported by nurses increased from 2-3% in 1995 to 12% 
in 2004 of total reporting [24]. 
An analysis of pharmacovigilance Italian databases 
showed that 74657 ADRs were received from differ-
ent categories of reporters, with only 1951 reports (ap-
proximately 2.6%) from nurses in the years 2004-2010 
[25]. Yet, Italian nurses are expected to report an ADR 
through the pharmacovigilance Italian system since 
2003 [26]. The reasons of under-reporting among Ital-
ian nurses have not been sufficiently explored and only 
one Italian study has described low skill of the hospital 
nurse staff in detecting ADRs. According to the au-
thors, this result is probably due to lack of knowledge 
on pharmacology and ADR [27]. 
Therefore, the aims of the present study was to de-
scribe nurses’ knowledge, attitudes and practices to-
wards spontaneous ADRs reporting.
MATERIAL AND METHODS
Study design 
This was a mixed-methods study and was conducted 
in line with the six-step guide for the WHO survey [28]. 
A multiphase design was used. This approach is used 
when researchers “examines a problem or topic through 
an iteration of connected quantitative and qualitative 
studies that are aligned sequentially, with each new ap-
proach building on what was learned previously to ad-
dress a central program objective” [29]. Thus, the study 
is built on 2 sequential quanti-qualitative phases: a de-
scriptive study that is followed by an explanatory focus 
group (Figure 1).
Phase 1: quantitative study
Instrument 
A questionnaire for knowledge, attitudes and prac-
tices of ADRs (KAP questionnaire) was developed by 
the research team and was based on an existing instru-
ment aimed at General Practitioners [30]. It consists 
of three sections and a section with socio demographic 
and professional data. 
The knowledge section of the KAP questionnaire is 
composed of 11 multi-choice questions and measures 
the theoretical knowledge about the pharmacovigilance 
in general and the reporting of suspected ADRs. An ex-
ample of item is: “the WHO definition of ADR”, “the 
aims of pharmacovigilance”, “the limitations of pre-
market studies on drugs”. Each item is composed of a 
statement or question with three possible response op-
tions, of which only one is correct (“0- wrong response”; 
“1- correct response”). Correct responses are summed 
up and converted into an 11-point score. 
The attitudes section of the KAP questionnaire con-
tains 6 items aimed to measure attitudes towards under-
reporting of suspect ADRs. The items are scored on a 
5-point Likert scale ranging from “1-Strongly disagree” 
to “5-Strongly agree”. An example of item is: “the ADR 
reporting is a bureaucratic process”, “I do not have time 
to report ADR during my work”, “the report of ADR is 
an exclusive duty of the physician”. Lower scores indi-
cated more positive attitude toward ADRs reporting. 
The practices section of the KAP questionnaire is 
composed of 7 questions and measures procedural 
knowledge and reporting practice. An example of item 
is: “I know where to find the ADR reporting form”, “I 
know how to fill and submit it”, “I reported an ADR in 
the last year”. Each item is dichotomous with two pos-
sible responses: “0-No” or “1-Yes”. Higher score indi-
cated a higher level of potential (procedural knowledge) 
or actual (number of reporting) practice in the report-
ing of suspected ADRs. 
Quantitative data collection
& analysis
Qualitative data collection
& analysis
Explanatory follow-up with
Figure 1
Study design.
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The socio-demographic section of the KAP question-
naire is used to collect variables such as gender, age, 
years of work experience, role, department affiliation. 
An additional question investigates the professional in-
terest for pharmacovigilance training.
Before administration, the KAP questionnaire under-
went validity and reliability testing. Initially, a group of 
pharmacoepidemiologists established its face-validity. 
Then the KAP underwent content validity with a group 
of nurses, further establishing its face-validity in nurs-
ing contests. Later, the KAP was administered to 22 
nurses to estimate test-retest reliability. Test-retest reli-
ability estimated with the interclass correlation coeffi-
cient (ICC) with a 2 week interval, was supportive with 
the following indices: ICC = 0.95, IC 95% 0.90-0.98 for 
the knowledge section; ICC = 0.99, IC 95% 0.98-0.99 
for the attitudes section; ICC = 0.92, IC 95% 0.82-0.92 
for practice section. 
Post-administration, the knowledge section of the 
KAP questionnaire underwent content validity using 
item analysis [31]. Then, the reliability of attitudes sec-
tion of the KAP questionnaire items was estimated with 
Cronbach’ alpha, while for the reliability of practices 
items Kuder-Richardson-20’ was used [32].
The item analysis indexes were: difficulty index (DI), 
discrimination power (DP) and distracters effectiveness 
(DE), and have been calculated using the software SITA 
(System for ITem Analysis) for the analysis of multiple 
choice tests and learning assessment [31]. As for the 
knowledge items, the DI showed a range between 30-
87% (mean = 62%) indicating a good balance between 
facility and difficulty on each item. The DP showed a 
value between 0.3-0.7 indicating a good consistency 
of each item with respects to the total item result. The 
DE showed a value ≠ 0 indicating good effectiveness of 
each distracter in the multiple choice tests.
Cronbach’s alpha was 0.70 for the attitudes section, 
while Kuder-Richardson-20’ coefficient was 0.82 for 
practices section. 
Procedures of data collection
The KAP was anonymously self-administered to all 
nurses employed in five public hospitals in Rome and 
its province. The only exclusion criterion adopted in the 
study was the prolonged (> 2 weeks) leave of absence 
from work. The respondents participated on a voluntary 
basis during their work and gave the completed ques-
tionnaire back after about a week from enrollment. 
Data analysis
All analyses were conducted using IBM software Sta-
tistical Package for Social Sciences (SPSS) version 15.0 
for Windows (SPSS Inc. Chicago, Illinois, USA).
A descriptive analysis was performed using frequen-
cies, mean and standard deviation for quantitative vari-
ables. 
Phase 2: qualitative study
The qualitative part of the study was conducted with 
a focus group. The main objective was to explain the 
discrepancies between the declared and the actual prac-
tice of ADR reporting. The secondary objective was to 
explore the reasons of under-reporting and to identify 
strategies to improve ADR’s reporting according to the 
participant’s point of view.
The research hypothesis was focused on a possible 
misinterpretation of the meaning of “ADR reporting”. 
ADR reporting is a structured process where a citizen 
or a health professional recognizes a suspect ADR, find 
and fill in the reporting form and send it to the Pharma-
covigilance System. Data emerging from the quantita-
tive study suggest that nurses might declare to “have 
reported suspect ADRs” when they simply “report” it to 
the doctor, to the nurse manager or in the patient’s or 
other clinical records. 
Instrument
Data was collected with a focus group performed 
according to the needs emerging from the descriptive 
study. 
Procedures of data collection
A theoretical sample of nurses was involved in a focus 
group. We selected the hospital where nurses declared 
to have reported ADRs but no records were found in 
the pharmacovigilance system. Nurses have been re-
cruited in the hospital units where ADRs reporting is 
expected to be higher. The audio-recorded focus group 
has been facilitated by and experienced researcher 
using pre-defined semi-structured questions. The ob-
jectives and methodology of data collection and data 
treatment have been explained by the facilitator at the 
beginning of the meeting and all participants signed a 
consent form. 
Data analysis
Data has been analyzed with NVivo 9.0. The audio 
recording have been listened, re-listened and coded 
deductively, according to the research objectives, and 
inductively, seeking new or unexpected contents. 
RESULTS
Quantitative study
Sample characteristic
The sample was composed of 570 hospital nurses and 
head nurses (response rate 73.8%). Participant ranged 
in age from 22-60 years (mean = 37.68; SD = 8.72). 
Most nurses were women and working in emergency 
departments. Their professional experience ranged 
from less than one year to 40 years (mean = 13.07; SD 
= 9.23). 87.4% (n = 498) would be interested in partici-
pating in training program on Pharmacovigilance and 
ADRs reporting. The socio-demographic characteristic 
are summarized in Table 1. 
Nurses’ knowledge, attitudes and practices
Knowledge score was calculated on a scale of 0-11 
(mean = 6.56, SD = 2.25, min = 0, max = 11). Atti-
tude score was calculated on a scale of 6-30 (mean = 
12.74; SD=3.91; min = 6, max = 26). As shown in Table 
2, only 20% (n = 113) of respondents considers that 
“ADR reporting is a bureaucratic process”, 17.7% (n = 
100) thinks that they “do not have time to report ADR” 
and 3.6% (n = 20) that “the data collected through the 
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reporting system have little utility”. Only 9.7% (n = 55) 
thinks that “the reporting could be used for legal pro-
ceedings against the reporter”, 5.1% (n = 29) that “my 
report of ADR does not make any difference”, 14.7% 
(n = 83) that “the report of ADR is an exclusive duty of 
the physician”.
 Practice score was calculated on a scale of 0-7 (mean 
= 1.76; SD = 2.05; min = 0, max = 7). Responders de-
clared that they were unaware of: the system of phar-
macovigilance (58.1%, n = 331); where to find the re-
porting form (63.5%, n = 362); how fill it in (71.6%, n 
= 408); to whom and how to send the reporting form 
(65.8%, n = 375); who is in charge of pharmacovigilance 
in their hospital (75.6%, n = 431). Finally, only 7.2% 
(n = 41) reported a suspect ADR in the last year and 
11.1% (n = 63) reported at least 3 suspect ADRs during 
their entire professional practice.
Qualitative study
An explanatory focus group has been organized in a 
hospital where nurses declared to have reported ADRs 
but no reports were found on the pharmacovigilance 
database. 
Fourteen nurses participated in the focus group, co-
ming from emergency care, radiology, surgery, nephro-
logy, cardiology, neonatal intensive care. One nurse was 
working at the Hospital Management. The mean age 
was 42 years (range 31-57), 10/14 were female nurses, 
Table 1
Nurses’ socio-demographic characteristics (n =  570)
Variables n (%)
Gender
Female 421 (73.9) 
Male 149 (26.1)
Age, mean (DS) 37.68 (8.72)
Professional role
Hospital nurses 548 (96.1)
Head hospital nurses 22 (3.9)
Years of work, mean (DS) 13.07 (9.23)
Places of work
Emergency Department 273 (47.9)
Department of Paediatrics, Obstetrics and Gynaecology  123 (21.6)
Department of Internal Medicine 71 (12.5)
Department of Surgery 58 (10.2)
Day hospital and outpatient services 45 (7.9)
Table 2 
Attitudes of under-reporting among nurses (n = 570)
Strongly 
disagree
n (%)
Disagree
n (%)
Neither
n (%)
Agree
n (%)
Strongly 
disagree
n (%)
Mean (SD)
ADR reporting is a  bureaucratic 
process.
155 (27.4) 191 (33.8) 106 (18.8) 73 (12.9) 40 (7.1) 2.38 (1.21)
I have no time to report ADR 
during my work.
142 (25.1) 229 (40.5) 94 (16.6) 76 (13.5) 24 (4.2) 2.31 (1.11)
The data collected through the 
reporting system have little utility.
199 (35.3) 259 (45.9) 86 (15.2) 10 (1.8) 10 (1.8) 1.89 (0.85)
The report could be used for legal 
proceedings against the reporter.
184 (32.6) 195 (34.5) 131 (23.2) 43 (7.6) 12 (2.1) 2.12 (1.02)
My report of ADR does not make 
an important contribution.
205 (36.2) 275 (48.6) 57 (10.1) 13 (2.3) 16 (2.8) 1.87 (0.89)
The report of ADR is only the duty 
of the physician.
185 (32.7) 212 (37.5) 85 (15.0) 56 (9.9) 27 (4.8) 2.16 (1.13)
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9/14 had a post-bachelor degree in nursing manage-
ment. The mean of professional experience was 17.7 
years (range 7-31). According to the answer to the data 
collection form, 12/14 declared to know the pharma-
covigilance system and 5/12 to have reported at least 1 
ADR during their nursing career. 
The main reasons for under-reporting in the parti-
cipant’s perception are lack of knowledge of the phar-
macovigilance system, unawareness of the nurse’s role 
within the pharmacovigilane system (“there is a lack of 
culture of ADRs reporting”) and fear of consequences, 
both as legal consequences and conflicts with doctors. 
The question focusing the meaning of “ADR reporting” 
revealed a spread misinterpretation. The nurses consi-
dered they were reporting suspect ADR’s while, in fact, 
they were merely informing the physician or the head 
nurses, or registering the suspected ADR in the pa-
tient’s clinical records. The participants expressed the 
need to improve the accessibility to the ADR reporting 
form through the intranet system and to provide speci-
fic communication or training interventions to improve 
their competencies in ADR reporting.
DISCUSSION
The quantitative and qualitative results explain the 
various aspects that relates to the spontaneous ADRs 
reporting among nurses. The results highlight the need 
to promote both knowledge and attitudes but along 
with organizational changes. Similarly, another study 
has indicated that the factors that condition the ADR 
reporting for the medical profession was both the in-
trinsic aspects related with the doctors’ knowledge and 
attitude, and the extrinsic aspects that include all tho-
se factors associated to the interaction with their work 
environment [33]. According to our findings, under-
reporting of ADRs among nurses could be mainly due 
to lack of knowledge and to heath care settings that do 
not support them in this activity.
The need to participate in specific training courses 
is strongly perceived among nurses to develop their 
knowledge and competencies in ADRs reporting, as 
emerging both in quantitative and qualitative findings. 
Previous studies have shown the importance of training 
to improve attitudes [20] and increase the number of 
reports of suspected ADRs among nurses [16, 20, 27]. 
Recently, a critical and systematic review on the strate-
gies to promote ADRs reporting indicated that 87% was 
educational interventions such as presentations, report 
reviews, Problem-Based Learning and clinical cases 
[34]. This means that training courses or other educa-
tional interventions should address, apart from the clas-
sical model of the learning to do, to be and to learn, the 
dimensions of the “know why”, as a lever for motivation 
and positive attitudes, changing routine practices into 
meaningful experiences. Even the systematic review 
conducted by Lopez-Gonzalez et al. [12] indicates that 
the attitudes and knowledge influence the under-repor-
ting among healthcare professionals more than their 
personal characteristics.
The procedural aspects of ADRs reporting system 
(who is the person in charge of pharmacovigilance in 
the hospital, where to find the reporting form, how fill it 
in, to whom and how to send the reporting form) were 
mainly unknown by the responders. In accordance with 
our results, a survey conducted in UK indicates that 
less than 50% of health care providers are aware of the 
national reporting system [35]. In other studies, some 
of the emerging barriers to nurses ADR reporting are 
the unavailability of the reporting form [36], the igno-
rance of how to fill it in [36, 37] and the unawareness 
of the pharmavigilance system functioning [38]. Chan-
ging and improving these aspects in health care settings 
might be very effective to increase ADRs reporting. In 
particular, a study indicated that giving a feedback after 
reporting could encourage the heath care provider in 
this activity [37]. 
Other specific reasons of under-reporting among 
nurses emerges in qualitative findings. In fact, there is 
a misinterpretation of the meaning of “reporting” and 
an unawareness of nurses’ autonomy in ADRs repor-
ting. In line with this, previous research has shown that 
suspect ADRs was communicated only verbally in 75% 
of cases by the nurses who said that they had reported 
(42.7%) [36]. In other studies, nurses do not consider 
the reporting of ADRs as an activity they are expected 
to perform autonomously: nurses tend to inform the 
physician of suspect ADRs and leave him the deci-
sion of reporting it [20, 39-40]. Furthermore, fear of 
consequences after ADR reporting emerges from the 
qualitative findings. Yet, previous studies have shown 
how this factor was associated with the belief of ha-
ving legal liability following ADR reporting [20, 39-
41]. Misinterpretation of the meaning of “reporting”, 
unawareness of nurses’ autonomy, fear of consequen-
ces could be due to ignorance regarding the activity of 
ADR reporting and possible training should focus on 
these aspects.
The study has some limitations due to the descripti-
ve and qualitative character, the heterogeneity of the 
sample and of health care settings where the study 
was conducted. Furthermore, the data were collected 
in one Italian region which not represent all nurses in 
Italy. In line with this, wide variations in the contents 
of the courses regarding the pharmacovigilance could 
exist across universities and regions. Although these li-
mits influence the generalizability of results, this study 
provides valuable insights to improve the understanding 
of ADRs reporting among nurses.
CONCLUSIONS 
In order to enhance the Italian pharmacovigilance 
system, an “ADRs reporting culture” should be pro-
moted with the contribution of all healthcare providers 
including nurses. At present, nurses are not fully aware 
of their active role in ADR reporting. Different actions 
might be proposed to integrate ADR reporting into 
nursing practice. The under-reporting phenomenon 
among hospital nurses is associated with knowledge, 
attitudes and organizational factors. These results are 
valuable for the pharmacovigilance system as all these 
factors can be modified setting up appropriate educa-
tional interventions and management changes. 
This is one of few studies which have explored nurses’ 
reporting of ADRs in Italy. Further research is needed 
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to investigate the barriers and the obstacles associated 
with nurses’ under-reporting. It is necessary to assess 
the mutual influence of knowledge, attitudes and prac-
tice and the burden of organizational aspects on ADR 
reporting. 
From a public health perspective and according to the 
new European Union Pharmacovigilance legislation, 
improving strategies for spontaneous ADRs reporting 
is one of the keys to reducing the risks and increasing 
the benefits of the use of drugs. 
Acknowledgments
The authors are grateful to Pharmacovigilance Com-
mittee of the Lazio Region for their support in conduc-
ting the study.
Conflict of interest statement 
No conflict of interest to declare.
Received on 18 February 2015.
Accepted on 21 May 2015.
REfERENCES
1. World Health Organization. The importance of pharmaco-
vigilance: Safety monitoring of medicinal products. Geneva: 
WHO; 2002. Available from: http://apps.who.int/medi-
cinedocs/pdf/s4893e/s4893e.pdf.
2. World Health Organization. Safety of medicines in pub-
lic health programmes: Pharmacovigilance an essential 
tool. Geneva: WHO; 2006. Available from: www.who.
int/medicines/areas/quality_safety/safety_efficacy/
Pharmacovigilance_B.pdf?ua=1.
3. Lexchin J. Is there still a role for spontaneous reporting of 
adverse drug reactions? CMAJ 2006 ;174(2):191-2. 
4. Harmark L, van Grootheest AC. Pharmacovigilance: 
methods, recent developments and future perspectives. 
Eur J Clin Pharmacol 2008;64(8):743-52. DOI: 10.1007/
s00228-008-0475-9.
5. European Medicines Agency. Guideline on good pharmacovig-
ilance practices (GVP). HMA-EMA; 2014. Available from: 
www.ema.europa.eu/docs/en_GB/document_library/ 
Scientific_guideline/2012/06/WC500129135.pdf.
6. Agenzia Italiana del farmaco. La nuova normativa di 
Farmacovigilanza. AIFA; Available from: www.agenzia-
farmaco.gov.it/sites/default/files/la_nuova_normativa_di_
farmacovigilanza_0.pdf.
7. European Commission (EU). Pharmacovigilance Impact 
Assessment 2008. Commission Staff Working Document. 
2670 Volume I. 2008. Available from: http://ec.europa.eu/
health/files/pharmacos/pharmpack_12_2008/pharmaco-
vigilance-ia-vol1_en.pdf.
8. Sultana J, Cutroneo P, Trifirò G. Clinical and economic 
burden of adverse drug reactions. J Pharmacol Pharma-
cother 2013;4(Suppl 1):S73-7. DOI: 10.4103/0976-500X. 
120957.
9. Marcum ZA, Pugh MJV, Amuan ME, Aspinall SL, Han-
dler SM, Ruby CM, et al. Prevalence of Potentially Pre-
ventable Unplanned Hospitalizations Caused by Thera-
peutic Failures and Adverse Drug Withdrawal Events 
Among Older Veterans. J Gerontol A Biol Sci Med Sci 
2012;67(8):867-74. DOI: 10.1093/gerona/gls001.
10. Hazell L, Shakir SAW. Under-reporting of adverse drug 
reactions - A systematic review. Drug Saf 2006;29(5):385-
96.
11. Inman WHW. Attitudes to adverse drug-reaction report-
ing. Br J Clin Pharmacol 1996;41(5):434-5.
12. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Deter-
minants of Under-Reporting of Adverse Drug Reactions 
A Systematic Review. Drug Saf 2009;32(1):19-31. DOI: 
10.2165/00002018-200932010-00002.
13. Vallano A, Cereza G, Pedros C, Agusti A, Danes I, Agu-
ilera C, et al. Obstacles and solutions for spontaneous 
reporting of adverse drug reactions in the hospital. Br J 
Clin Pharmacol 2005;60(6):653-8. 
14. Arnold GJ. Clinical recognition of adverse drug reactions: 
Obstacles and opportunities for the nursing profession. J 
Nurs Care Qual 1998;13(2):45-55.
15. Griffith R. Nurses must report adverse drug reactions. Br 
J Nurs 2013;22(8):484-5. 
16. Valente S, Murray L, Fisher D. Nurses improve medica-
tion safety with medication allergy and adverse drug re-
ports. J Nurs Care Qual 2007;22(4):322-7.
17. Bobay K, Gentile DL, Hagle ME. The relationship of 
nurses’ professional characteristics to levels of clinical 
nursing expertise. Appl Nurs Res 2009;22(1):48-53. DOI: 
10.1016/j.apnr.2007.03.005.
18. Lim AG, Honey M. New Zealand newly graduated 
nurses medication management: results of a survey. 
Nurse Educ Pract 2014;14(6):660-5. DOI: 10.1016/j.
nepr.2014.08.005. 
19. Nursing and Midwifery Council. Standards for medicines 
management. London: NMC; 2008. Available from: www.
nmc-uk.org/Documents/NMC-Publications/NMC-Stan-
dards-for-medicines-management.pdf.
20. Hanafi S, Torkamandi H, Hayatshahi A, Gholami K, 
Shahmirzadi NA, Javadi MR. An educational interven-
tion to improve nurses’ knowledge, attitude, and practice 
toward reporting of adverse drug reactions. Iran J Nurs 
Midwifery Res 2014;19(1):101-6.
21. Backstrom M, Ekman E, Mjorndal T. Adverse drug reac-
tion reporting by nurses in Sweden. Eur J Clin Pharmacol 
2007;63(6):613-8.
22. Morrison-Griffiths S, Walley TJ, Park BK, Breckenridge 
AM, Pirmohamed M. Reporting of adverse drug reac-
tions by nurses. Lancet 2003;361(9366):1347-8.
23. Mendes D, Alves C Batel, Marques F. Nurses’ spontane-
ous reporting of adverse drug reactions: expert review of 
routine reports. J Nurs Manag 2014;22(3):322-30. DOI: 
10.1111/jonm.12003.
24. Ulfvarson J, Mejyr S, Bergman U. Nurses are increasingly 
involved in pharmacovigilance in Sweden. Pharmacoepide-
miol Drug Saf 2007;16(5):532-7.
25. Conforti A, Opri S, D’Incau P, Sottosanti L, Moretti 
U, Ferrazin F, et al. Adverse drug reaction reporting by 
nurses: analysis of Italian pharmacovigilance database. 
Pharmacoepidemiol Drug Saf 2012;21(6):597-602. DOI: 
10.1002/pds.3225.
26. Italia. Decreto Legislativo 8 aprile 2003, n. 95. Attu-
azione della direttiva 2000/38/CE relativa alle specialità 
medicinali. Gazzetta Ufficiale - Serie Generale n. 101, 3 
maggio 2003.
27. Opri S, D’Incau P, Meglioranzi M, Pignata C, Brasola S, 
Conforti A, et al. Venus study: a research and education 
project on nurses and drug surveillance. Assist Inferm Ric 
2011;30(1):6-15.
28. World Health Organization. Advocacy, communication 
and social mobilization for TB control: a guide to developing 
Nurses’ adverse drug reactioN reportiNg
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
283
knowledge, attitude and practice surveys. Geneva: WHO; 
2008. Available from: http://whqlibdoc.who.int/publica-
tions/2008/9789241596176_eng.pdf.
29. Creswell JW, Plano Clark VL. Designing and conducting 
mixed methods research (2 ed). Thousand Oaks, CA: Sage; 
2011.
30. Caffari B, Giusti A, Nati G, Raschetti R. I percorsi della 
formazione per la farmacovigilanza nella Regione Lazio: 
costruzione e valutazione. In: XII Conferenza Nazionale di 
Sanità Pubblica. Roma: Ottobre 12-15, 2011. Atti. Roma: 
Società Italiana di Igiene (SItI); 2011. p. 683. 
31. Massari M, Giusti A, Maggini M, Barbariol P, Raschetti 
R. Valutazione della formazione in salute pubblica: il software 
SITA (Sistema per l’ITem Analysis). Roma: Istituto Supe-
riore di Sanità; 2009. (Rapporti ISTISAN 09/28). Avail-
able from: www.iss.it/binary/publ/cont/09_28_web.pdf.
32. Barbaranelli C, D’Olimpo F. Analisi dei dati con SPSS.I. 
Le analisi di base. Milano: LED; 2007.
33. Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. 
Factors that influence spontaneous reporting of adverse 
drug reactions: a model centralized in the medical profes-
sional. J Eval Clinical Pract 2004;10(4):483-9.
34. Gonzalez-Gonzalez C, Lopez-Gonzalez E. Herdeiro 
MT, Figueiras A. Strategies to improve adverse drug re-
action reporting: a critical and systematic review. Drug 
Saf 2013;36:317-28. DOI: 10.1007/s40264-013-0058-2.
35. Pulford A, Malcolm W. Knowledge and attitudes to report-
ing adverse drug reactions. Br J Nurs 2010;19(14):899-
904.
36. Fadare JO, Enwere OO, Afolabi AO, Chedi BAZ, Musa 
A. Knowledge, Attitude and Practice of Adverse Drug 
Reaction Reporting among Healthcare Workers in a 
Tertiary Centre in Northern Nigeria. Trop J Pharm Res 
2011;10:235-42. DOI: 10.4314/tjpr.v10i3.4. Available 
from: www.tjpr.org/vol10_no3/2011_10_3_1_Fadare.pdf.
37. Ekman E, Petersson G, Tagerud S, Backstrom M. Aware-
ness among nurses about reporting of adverse drug reac-
tions in Sweden. Drug Healthc Patient Saf 2012;4:61-6. 
DOI: 10.2147/DHPS.S31103.
38. Li Q, Zhang SM, Chen HT, et al. Awareness and at-
titudes of healthcare professionals in Wuhan, China 
to the reporting of adverse drug reactions. Chin Med J 
2004;117(6):856-61.
39. Hanafi S, Torkamandi H, Hayatshahi A, Gholami K, Ja-
vadi M. Knowledge, attitudes and practice of nurse re-
garding adverse drug reaction reporting. Iran J Nurs Mid-
wifery Res 2012;17(1):21-5.
40. Hajebi G, Mortazavi SA, Salamzadeh J, Zian A. A Survey 
of Knowledge, Attitude and Practice of Nurses towards 
Pharamacovigilance in Taleqani Hospital. Iran J Pharm 
Res 2010;9(2):199-206.
41. Hamedivafa F, Peiravian F. A survey of knowledge, atti-
tude and practice of nurses towards pharmacovigilance in 
teaching hospital, Qazvin-Iran. In: 13th Iranian Pharma-
ceutical Sciences Congress. Isfahan (Iran): September 3-6, 
2012. Research in Pharmaceutical Sciences 2012;7(5):S863. 
Available from: http://rps.mui.ac.ir/index.php/jrps/article/
viewFile/906/1430.
